Home › Research › Treatments
Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying
Knopman D.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2006-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
There are many who feel that the achievement of a disease-modifying (DM) designation for a drug is an important goal in Alzheimer disease (AD) therapeutics. Several designs that might prove DM have been proposed, including randomized start, randomized withdrawal, and slope analysis. Using biomarkers such as cerebrospinal fluid assays or imaging features as primary outcome measures have also been considered a way of proving DM. The available methods for establishing DM are fraught with logistical and analytic problems. Unless the drug's benefits are large, attempts to prove DM for a truly effective drug may fail. Therefore, clinical trial designs that are the simplest to conduct and interpret are superior to those more complex approaches intended to prove DM.
What this study adds
Evidence grade: High
This is an opinion paper arguing that finding effective Alzheimer's drugs matters more than proving they are disease-modifying. It states that current methods for establishing disease modification have logistical and analytic problems and may fail even for truly effective drugs.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Knopman, D. (2006). Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1016/j.jalz.2006.03.010
Vancouver
Knopman D. Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2006. doi:10.1016/j.jalz.2006.03.010. PMID: 19595873.
BibTeX
@article{knopman2006-19595873,
author = {Knopman, D.},
title = {{Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2006},
doi = {10.1016/j.jalz.2006.03.010},
pmid = {19595873},
url = {https://doi.org/10.1016/j.jalz.2006.03.010}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Several designs that might prove DM have been proposed, including randomized start, randomized withdrawal, and slope analysis.
- Using biomarkers such as cerebrospinal fluid assays or imaging features as primary outcome measures have also been considered a way of proving DM.
- The available methods for establishing DM are fraught with logistical and analytic problems.
- Unless the drug's benefits are large, attempts to prove DM for a truly effective drug may fail.
- Therefore, clinical trial designs that are the simplest to conduct and interpret are superior to those more complex approaches intended to prove DM.
Why it matters
This is an opinion paper arguing that finding effective Alzheimer's drugs matters more than proving they are disease-modifying. It states that current methods for establishing disease modification have logistical and analytic problems and may fail even for truly effective drugs.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 38/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2006 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 22 year(s) since 2006 |
| Impact for its field and year | 1 / 6 | Cited 1.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author David S. Knopman: h-index 188 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Mayo Clinic: institution h-index 1,606 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19595873) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also in Treatments
194 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.